Pfizer Inc (LTS:0Q1N)
$ 27.58 +0.090 (+0.33%) Market Cap: 157.99 Bil Enterprise Value: 209.79 Bil PE Ratio: 36.47 PB Ratio: 1.85 GF Score: 68/100

Pfizer Inc. at Morgan Stanley Global Healthcare Conference Transcript

Sep 14, 2026 / 02:45PM GMT
Terence Flynn
Morgan Stanley - Analyst

Great. Good morning. Thanks for joining us. I'm Terence Flynn, Morgan Stanley's US Biopharma analyst. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative.

Well, I'm very pleased to be hosting Pfizer this morning at our conference. Thanks so much to Albert Bourla, who's the company's CEO and Chairman. I'm very happy to be here with you, Albert. And maybe I'll turn over to you to just make some opening remarks before we launch into Q&A. But again, thanks for taking time out of your day.

Albert Bourla
Pfizer Inc. - Chairman of the Board, Chief Executive Officer

Thank you for the invitation. Good morning, everyone. I mean, very few comments in the beginning, I think that Pfizer is in a good place right now. We had three serious headwinds in 2025 that I think

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot